Press room | News

Sep 18, 2018

Sosei Provides Update on HTL0018318

Jun 4, 2018

Sosei Announces Appointment of Chris Cargill as Interim CFO

May 24, 2018

Sosei collaboration with PeptiDream progressing well - Peptide antagonists with high affinity and selectivity against PAR2 target identified

May 16, 2018

Sosei Group Corporation: Notice Regarding Appointment of New External Directors

May 10, 2018

Sosei - Consolidated Financial Results for the Full Year 2017

Apr 18, 2018

Sosei confirms new data demonstrating AZD4635, a novel A2A receptor antagonist, induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical models

Mar 14, 2018

Sosei today hosted an Investor Day in Tokyo

Mar 13, 2018

Sosei Regains Worldwide Rights from Teva to Develop and Commercialize Novel Small Molecule CGRP Antagonists for Migraine and Other Severe Headaches

Feb 14, 2018

Sosei - Consolidated Financial Results for the Third Period FY2017

Feb 8, 2018

Sosei provides an update on its immuno-oncology clinical program with AstraZeneca

Jan 19, 2018

Changes in Executive Management at Sosei

Jan 10, 2018

Sosei subsidiary, Heptares, enters drug R&D collaboration with Imperial College London focused on multiple GPCR disease target opportunities in the gastro-intestinal tract

Jan 4, 2018

Heptares scientists solve structure of complement C5a receptor, an important drug target for inflammatory and neurodegenerative diseases, and cancer

Nov 9, 2017

Sosei to Advance Clinical Development in Japan of HTL0018318 in Patients with Dementia with Lewy Bodies

Nov 9, 2017

Sosei - Consolidated Financial Results for the Second Period FY2017

Oct 5, 2017

Heptares Founder Richard Henderson Receives Nobel Prize in Chemistry 2017 for Pioneering Work in Cryo-EM for Visualising Biological Structures

Sep 1, 2017

First Subject Dosed in Phase 1 Clinical Study of Novel Selective Muscarinic M4 Agonist in Development to Treat Major Symptoms of Alzheimer’s Disease

Sep 1, 2017

Heptares Enters a New Research and Drug Discovery Collaboration under its “ORBIT” Initiative with Juntendo University

Jul 13, 2017

Heptares Hosts Scientific Symposium in Celebration of 10-Year Anniversary

Jun 29, 2017

Heptares and PeptiDream Enter Strategic Collaboration to Discover, Develop and Commercialise Novel Therapeutics in Inflammatory Disease

Jun 28, 2017

Heptares enters a New Research and Drug Discovery Collaboration under its “ORBIT” Initiative with New York University School of Medicine

Jun 20, 2017

Heptares Plans Relocation to Cambridge, UK

May 31, 2017

Heptares Solves First Full-length Structure of GLP-1 Receptor Bound to Peptide Agonist

May 18, 2017

Heptares to Receive US$5 Million Milestone Payment from Teva

May 18, 2017

Heptares Co-founder and CSO, Fiona Marshall, Receives 2017 John Daly Lecture Award in Recognition of her Outstanding Contribution to GPCR Drug Discovery

Apr 27, 2017

Heptares Collaboration with AstraZeneca yields New Insights to Advance Drug Discovery in Pain, Cancer and Inflammation

Apr 5, 2017

Heptares to Receive US$12 Million Milestone Payment from AstraZeneca

Mar 13, 2017

Heptares enters Agreement with Daiichi Sankyo to Discover and Develop Novel, Small Molecules for the Treatment of Pain

Jan 31, 2017

Heptares Enters a New Research Collaboration under its "ORBIT" Initiative with the University of Cambridge

Dec 8, 2016

Heptares Scientists Solve Structure of CCR9 Chemokine Receptor offering Unique Opportunity to Apply Structure-Based Design across Chemokine Receptor Family

Nov 30, 2016

Heptares to Acquire G7 Therapeutics to Extend Leadership in GPCR-Focused Drug Discovery and Development

Nov 10, 2016

Jitsubo and Heptares Therapeutics to develop novel GPCR-targeting peptide candidates for severe gastro-intestinal disorders

Oct 7, 2016

Heptares wins Best Established Biotech Company Award at OBN Annual Awards 2016

Jul 6, 2016

Initiation of Phase 1 Clinical Study with Novel Immuno-Oncology Candidate Triggers US$10 Million Milestone Payment from AstraZeneca

Jun 29, 2016

Heptares and leadXpro Enter Collaboration on Powerful New Approaches to GPCR Structure Determination for Drug Discovery

May 26, 2016

Hart-Scott-Rodino Clearance for Global Collaboration between its Subsidiary Heptares Therapeutics and Allergan

Apr 28, 2016

Heptares CSO and Co-founder - Dr Fiona Marshall - Elected as a Fellow of The Academy of Medical Sciences

Apr 25, 2016

Heptares Scientists Solve Structures of GLP-1 and Glucagon Receptors enabling Structure-Based Design for Metabolic Disease

Apr 18, 2016

Heptares and Kymab enter Strategic Collaboration to Discover, Develop and Commercialise Novel Antibody Therapeutics

Apr 6, 2016

Allergan and Heptares Announce Global R&D and Commercialization Partnership for Novel Treatments in Alzheimer’s and Other Neurological Disorders

Apr 4, 2016

Heptares Joins Pharma Consortium Applying State-of-the-Art Cryo-Electron Microscopy to Advance Structure-Based Drug Discovery

Feb 10, 2016

Heptares Announces Positive Results from Phase 1b Clinical Trial with HTL9936, a First-In-Class Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Dementia and Schizophrenia

Feb 2, 2016

Heptares Launches “ORBIT” Initiative - A New Collaborative Drug R&D Programme for Industry and Academia Focused on G Protein-Coupled Receptors (GPCRs)

Back to top

Other News

© 2012-2018 Heptares Therapeutics